Curis, Inc. (CRIS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Curis, Inc. (CRIS) closed at USD 0.60 on 2026-10-14, a change of -98 % over the past year, with a market capitalization of USD 1.23M.

Curis, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Curis, Inc. key figures

Previous close

USD 0.60 (2026-10-14)

1-year change

-98 %

Market cap

USD 1.23M

Enterprise value

USD -2.97M

P/E ratio (trailing)

0.47

P/E ratio (forward)

-0.08

EPS (trailing)

1.09

EPS (forward)

-6.01

PEG ratio

n/a

Price to book

0.21

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.20

Employees

20

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Curis, Inc. and compare it with other stocks.